{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:40:44Z","timestamp":1784994044271,"version":"3.55.0"},"reference-count":42,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"unspecified","delay-in-days":51,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Familial hypercholesterolaemia (FH) is a hereditary disorder characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels, substantially increasing the risk of atherosclerotic cardiovascular disease. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) targeting therapies, including monoclonal antibodies and small interfering RNA (siRNA) agents, have emerged as effective lipid lowering therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of PCSK9-targeting therapy on lipid biomarkers and adverse events in patients with FH, compared with placebo on the background of standard lipid-lowering therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted, incorporating data from 23 randomised controlled trials involving adult and paediatric FH patients treated with PCSK9 inhibitors (PCSK9i) or siRNA, including alirocumab, bococizumab, evolocumab, tafolecimab and inclisiran. Eligible studies reported changes in LDL-C, apolipoprotein B (ApoB), lipoprotein a (Lp(a)), triglycerides (TGL) and adverse effects. Pooled mean differences (MDs) and ORs with 95% CIs were calculated using random-effects models, and heterogeneity was assessed with I\u00b2 statistic. This meta-analysis was registered on PROSPERO (CRD42025631510).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 4282 patients were included. PCSK9-targeting therapies significantly reduced LDL-C levels compared with control therapies (MD=\u221246.64%; 95%\u2009CI \u221250.77% to \u201342.52%; p&lt;0.00001) and TGL (MD=\u221215.18%; 95%\u2009CI \u201319.34% to \u201311.03%; p&lt;0.00001). Significant reductions were also observed for ApoB (MD=\u221234.94%; 95%\u2009CI \u201340.89% to \u201328.99%; p&lt;0.00001) and Lp(a) (MD=\u221222.7%; 95%\u2009CI \u221225.95% to \u201319.44%; p&lt;0.00001). LDL-C, TGL and ApoB reduction were more significant in heterozygous FH patients than in homozygous patients. The safety profile of these therapies was favourable, with adverse event rates comparable to those of the controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PCSK9i and Inclisiran demonstrate significant and sustained reductions in LDL-C, ApoB, Lp(a) and TGL in FH patients, especially in heterozygous FH patients. These agents are generally well-tolerated and represent effective treatment options for FH patients inadequately controlled by standard lipid-lowering therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003490","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T10:30:15Z","timestamp":1755772215000},"page":"e003490","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8434-552X","authenticated-orcid":false,"given":"Vinh Q T","family":"Ho","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghi Bao","family":"Tran","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giang Son","family":"Arrighini","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Downes","sequence":"additional","affiliation":[{"name":"Department of Rural Medicine, University of New England, Armidale, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrunalini","family":"Dandamudi","sequence":"additional","affiliation":[{"name":"St Barnabas Health System Bronx, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Zecchin","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri Huynh Quang","family":"Ho","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, Ho Chi Minh City Heart Institute, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7832-6463","authenticated-orcid":false,"given":"Hemank","family":"Walia","sequence":"additional","affiliation":[{"name":"Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Barbagelata","sequence":"additional","affiliation":[{"name":"Universidad Catolica Argentina, Buenos AIres, Argentina"},{"name":"Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten M","family":"Leucker","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Hospital Sirio-Libanes, S\u00e3o Paulo, Brazil"},{"name":"Hospital Albert Einstein, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2026010701105426000_12.2.e003490.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044795"},{"key":"2026010701105426000_12.2.e003490.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.04.003"},{"key":"2026010701105426000_12.2.e003490.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv157"},{"key":"2026010701105426000_12.2.e003490.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"2026010701105426000_12.2.e003490.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu274"},{"key":"2026010701105426000_12.2.e003490.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2026010701105426000_12.2.e003490.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625"},{"key":"2026010701105426000_12.2.e003490.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.02.019"},{"key":"2026010701105426000_12.2.e003490.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004215"},{"key":"2026010701105426000_12.2.e003490.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"2026010701105426000_12.2.e003490.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"2026010701105426000_12.2.e003490.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"2026010701105426000_12.2.e003490.13","doi-asserted-by":"crossref","unstructured":"Huo Y , Chen B , Lian Q , et al . Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet Reg Health West Pac 2023;41. doi:10.1016\/j.lanwpc.2023.100907","DOI":"10.1016\/j.lanwpc.2023.100907"},{"key":"2026010701105426000_12.2.e003490.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105803"},{"key":"2026010701105426000_12.2.e003490.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"2026010701105426000_12.2.e003490.16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"2026010701105426000_12.2.e003490.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"2026010701105426000_12.2.e003490.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387"},{"key":"2026010701105426000_12.2.e003490.19","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. doi:10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2026010701105426000_12.2.e003490.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.03.088"},{"key":"2026010701105426000_12.2.e003490.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019910"},{"key":"2026010701105426000_12.2.e003490.22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamapediatrics.2023.6477","article-title":"Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"178","author":"Santos","year":"2024","journal-title":"JAMA Pediatr"},{"key":"2026010701105426000_12.2.e003490.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60771-5"},{"key":"2026010701105426000_12.2.e003490.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw388"},{"key":"2026010701105426000_12.2.e003490.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"2026010701105426000_12.2.e003490.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.027"},{"key":"2026010701105426000_12.2.e003490.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.144055"},{"key":"2026010701105426000_12.2.e003490.28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"The Lancet"},{"key":"2026010701105426000_12.2.e003490.29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"The Lancet"},{"key":"2026010701105426000_12.2.e003490.30","doi-asserted-by":"crossref","unstructured":"Chai M , He Y , Zhao W , et al . Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med 2023;21. doi:10.1186\/s12916-023-02797-8","DOI":"10.1186\/s12916-023-02797-8"},{"key":"2026010701105426000_12.2.e003490.31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, Safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"2026010701105426000_12.2.e003490.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913805"},{"key":"2026010701105426000_12.2.e003490.33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5551\/jat.64454","article-title":"Efficacy, safety, and pharmacokinetics of inclisiran in japanese patients: results from ORION-15","volume":"31","author":"Yamashita","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"2026010701105426000_12.2.e003490.34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jacasi.2023.09.006","article-title":"Efficacy and safety of inclisiran in Asian patients: results from ORION-18","volume":"4","author":"Huo","year":"2024","journal-title":"JACC Asia"},{"key":"2026010701105426000_12.2.e003490.35","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","article-title":"Efficacy and safety of long-term evolocumab use among Asian subjects - a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial","volume":"85","author":"Keech","year":"2021","journal-title":"Circ J"},{"key":"2026010701105426000_12.2.e003490.36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00592-021-01703-z","article-title":"Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting","volume":"58","author":"Scicali","year":"2021","journal-title":"Acta Diabetol"},{"key":"2026010701105426000_12.2.e003490.37","doi-asserted-by":"crossref","unstructured":"Bosco G , Di Giacomo Barbagallo F , Di Marco M , et al . Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Prog Cardiovasc Dis 2025. doi:10.1016\/j.pcad.2025.05.008","DOI":"10.1016\/j.pcad.2025.05.008"},{"key":"2026010701105426000_12.2.e003490.38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","article-title":"Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)","volume":"366","author":"Gargiulo","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026010701105426000_12.2.e003490.39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13219","article-title":"Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study","volume":"290","author":"Casula","year":"2021","journal-title":"J Intern Med"},{"key":"2026010701105426000_12.2.e003490.40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2021.04.008","article-title":"Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe\/placebo in patients at high cardiovascular risk","volume":"326","author":"Ma","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026010701105426000_12.2.e003490.41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.042","article-title":"A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia","volume":"325","author":"Brandts","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026010701105426000_12.2.e003490.42","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000789"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:11:18Z","timestamp":1767777078000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,21]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/openhrt-2025-003490"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003490","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}